CN1522159A - 干扰素配制品 - Google Patents

干扰素配制品 Download PDF

Info

Publication number
CN1522159A
CN1522159A CNA028131215A CN02813121A CN1522159A CN 1522159 A CN1522159 A CN 1522159A CN A028131215 A CNA028131215 A CN A028131215A CN 02813121 A CN02813121 A CN 02813121A CN 1522159 A CN1522159 A CN 1522159A
Authority
CN
China
Prior art keywords
interferon
polypeptide
composition according
interferon gamma
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028131215A
Other languages
English (en)
Chinese (zh)
Inventor
乔恩・德鲁斯特拉普
乔恩·德鲁斯特拉普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen Holdings Ltd
Maxygen Inc
Original Assignee
Maxygen Holdings Ltd
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd, Maxygen Inc filed Critical Maxygen Holdings Ltd
Publication of CN1522159A publication Critical patent/CN1522159A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA028131215A 2001-06-29 2002-06-28 干扰素配制品 Pending CN1522159A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200101040 2001-06-29
DKPA200101040 2001-06-29
DKPA200101277 2001-08-30
DKPA200101277 2001-08-30
DKPA200200257 2002-02-19
DKPA200200257 2002-02-19

Publications (1)

Publication Number Publication Date
CN1522159A true CN1522159A (zh) 2004-08-18

Family

ID=27222516

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028131215A Pending CN1522159A (zh) 2001-06-29 2002-06-28 干扰素配制品

Country Status (7)

Country Link
EP (1) EP1414498A2 (enExample)
JP (1) JP2004522803A (enExample)
CN (1) CN1522159A (enExample)
CA (1) CA2452364A1 (enExample)
MX (1) MXPA03011793A (enExample)
RU (1) RU2004102500A (enExample)
WO (1) WO2003002152A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101686681A (zh) * 2007-04-27 2010-03-31 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
CN109689087A (zh) * 2016-05-13 2019-04-26 奥里尼斯生物科学公司 靶向性突变干扰素-β及其用途
CN111358938A (zh) * 2020-03-30 2020-07-03 温州肯恩大学(Wenzhou-KeanUniversity) 人干扰素-ε与干扰素-γ组合药及用途

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
RS20050502A (sr) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
US7846427B2 (en) 2003-12-11 2010-12-07 Ares Trading S.A. Stabilized interferon liquid formulations
BRPI0510527A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
US20070212306A1 (en) * 2004-06-07 2007-09-13 Quay Steven C Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
SG155183A1 (en) * 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
WO2007101949A2 (fr) * 2006-03-08 2007-09-13 Biomethodes Variants de l'interferon- gamma humain (infgamma)
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
EP2102355B1 (en) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
ES2387236T3 (es) 2007-12-20 2012-09-18 Merck Serono S.A. Formulaciones de interferón beta pegilado
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
AR074357A1 (es) * 2008-11-17 2011-01-12 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro
KR101743591B1 (ko) 2009-05-13 2017-06-20 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
RU2482871C2 (ru) * 2010-06-07 2013-05-27 Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") Композиция для лечения вирусных заболеваний животных
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US10012064B2 (en) 2015-04-09 2018-07-03 Highlands Natural Resources, Plc Gas diverter for well and reservoir stimulation
US10344204B2 (en) 2015-04-09 2019-07-09 Diversion Technologies, LLC Gas diverter for well and reservoir stimulation
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
US10982520B2 (en) 2016-04-27 2021-04-20 Highland Natural Resources, PLC Gas diverter for well and reservoir stimulation
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CA3108066A1 (en) * 2018-07-30 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
CN113797317B (zh) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 一种组合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6133248A (en) * 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101686681A (zh) * 2007-04-27 2010-03-31 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
US8853236B2 (en) 2007-04-27 2014-10-07 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
CN101686681B (zh) * 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
US9125945B2 (en) 2007-04-27 2015-09-08 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US9623045B2 (en) 2007-04-27 2017-04-18 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US10034947B2 (en) 2007-04-27 2018-07-31 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
CN109689087A (zh) * 2016-05-13 2019-04-26 奥里尼斯生物科学公司 靶向性突变干扰素-β及其用途
CN109689087B (zh) * 2016-05-13 2023-04-04 奥里尼斯生物科学私人有限公司 靶向性突变干扰素-β及其用途
CN111358938A (zh) * 2020-03-30 2020-07-03 温州肯恩大学(Wenzhou-KeanUniversity) 人干扰素-ε与干扰素-γ组合药及用途
CN111358938B (zh) * 2020-03-30 2023-08-11 温州肯恩大学(Wenzhou-KeanUniversity) 人干扰素-ε与干扰素-γ组合药及用途

Also Published As

Publication number Publication date
EP1414498A2 (en) 2004-05-06
JP2004522803A (ja) 2004-07-29
MXPA03011793A (es) 2004-04-02
RU2004102500A (ru) 2005-04-10
CA2452364A1 (en) 2003-01-09
WO2003002152A3 (en) 2003-05-01
WO2003002152A2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
CN1522159A (zh) 干扰素配制品
CN1188172C (zh) G－csf偶联物
CN1103782C (zh) 单聚乙二醇化的mgdf多肽
CN1038035C (zh) 聚乙二醇蛋白质结合物的制备方法
US20030138403A1 (en) Interferon formulations
CN1180839C (zh) 用于粘膜给药的含有聚合物药物的粉末制剂
CN1729018A (zh) G－csf偶联物
CN1993138A (zh) 稳定蛋白质的方法
HK1046694A1 (zh) 干扰素-α蛋白作为FC融合蛋白的表达和运输
CN1241638C (zh) Ifnar2/ifn复合物
CN1283659C (zh) 截短的神经胶质细胞系来源的神经营养因子
CN1309423C (zh) 干扰素γ偶联物
CN1897812A (zh) 糖聚乙二醇化的粒细胞集落刺激因子
CN101062419A (zh) 干扰素－β－1a的聚合物缀合物及其使用
CN1501815A (zh) 新的干扰素β-样分子
CN100339393C (zh) Hgf－nk4的peg－偶联物
CN1257186C (zh) 干扰素γ多肽变体
CN1816347A (zh) 不含人血清白蛋白的稳定化干扰素液体制剂
CN1161468C (zh) Mpl配体类似物
CN1802170A (zh) 利用IFN－β治疗慢性炎性脱髓鞘性多神经病
CN1187447C (zh) Mpl配体类似物
CN1684979A (zh) 糖基化的人干扰素α同种型
CN1622957A (zh) Ifnar2突变体,其制造和应用
CN1822852A (zh) 改良的重组人干扰素－β－1b多肽
HK1069834B (en) Interferon gamma polypeptide variants

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication